Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Comment: Ipilimumab in high risk stage III melanoma

ESMO 2016

7 - 11 Oct 2016

Published: 10 Oct 2016

Views: 2020

Rating:

Save

Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium

Dr De Azambuja talks to ecancertv at ESMO 2016 about the finding that ipilimumab as adjuvant therapy improved overall survival in high risk stage III melanoma.

Read the news story or watch the interview or press conference video with lead author, Prof Eggermont, for more.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial...

Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA

Mirvetuximab soravtansine and pembrolizumab combo shows promise in endometrial cancer subtype ( Dr Rebecca Porter - Dana-Farber Cancer Institute, Boston, USA )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma...

Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA

Adding new vaccine type to leading immunotherapy dramatically reduces melanoma recurrence ( Dr Jeffrey Weber - NYU Langone’s Perlmutter Cancer Center, Newyork, USA )

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA

Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly...

Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Treatment with tumour-infiltrating lymphocytes versus ipilimumab significantly improved PFS for advanced melanoma ( Dr John B Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer